<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Tenaya Therapeutics, Inc. — News on 6ix</title>
<link>https://6ix.com/company/tenaya-therapeutics-inc</link>
<description>Latest news and press releases for Tenaya Therapeutics, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 27 Apr 2026 12:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/tenaya-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835cc1278dffbe2df11d6e3.webp</url>
<title>Tenaya Therapeutics, Inc.</title>
<link>https://6ix.com/company/tenaya-therapeutics-inc</link>
</image>
<item>
<title>Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2-Associated ARVC at ASGCT 2026</title>
<link>https://6ix.com/company/tenaya-therapeutics-inc/news/tenaya-therapeutics-announces-late-breaking-oral-presentation-of-new-clinical-data-from-ridgetm-1-phase-1b2-clinical-trial-of-tn-401-gene-therapy-in-adults-with-pkp2-associated-arvc-at-asgct-2026</link>
<guid isPermaLink="true">https://6ix.com/company/tenaya-therapeutics-inc/news/tenaya-therapeutics-announces-late-breaking-oral-presentation-of-new-clinical-data-from-ridgetm-1-phase-1b2-clinical-trial-of-tn-401-gene-therapy-in-adults-with-pkp2-associated-arvc-at-asgct-2026</guid>
<pubDate>Mon, 27 Apr 2026 12:30:00 GMT</pubDate>
<description>Readout to Include One-Year Cohort 1 Results and Early Cohort 2 Data; Webcast Conference Call Planned to Review RIDGE-1 Data at ASGCT Additional Presentations at ASGCT Showcase Tenaya’s Work with Patients to Advance Gene Therapy and Early-Stage Pipeline Innovations in Cardiac Gene Editing SOUTH SAN FRANCISCO, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curat</description>
</item>
<item>
<title>Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/tenaya-therapeutics-inc/news/tenaya-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update-33</link>
<guid isPermaLink="true">https://6ix.com/company/tenaya-therapeutics-inc/news/tenaya-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update-33</guid>
<pubDate>Wed, 11 Mar 2026 04:00:00 GMT</pubDate>
<description>Reported Promising Data for TN-201 and TN-401 Gene Therapies in Fourth Quarter of 2025; Additional Data Readouts and Pursuit of Regulatory Alignment for Each</description>
</item>
<item>
<title>Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301’s Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy</title>
<link>https://6ix.com/company/tenaya-therapeutics-inc/news/tenaya-therapeutics-presents-preclinical-data-at-mda-2026-highlighting-tn-301s-potential-to-correct-skeletal-and-cardiac-muscle-decline-in-duchenne-muscular-dystrophy</link>
<guid isPermaLink="true">https://6ix.com/company/tenaya-therapeutics-inc/news/tenaya-therapeutics-presents-preclinical-data-at-mda-2026-highlighting-tn-301s-potential-to-correct-skeletal-and-cardiac-muscle-decline-in-duchenne-muscular-dystrophy</guid>
<pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
<description>Tenaya’s Highly Selective HDAC6 Inhibitor TN-301 Outperformed Approved Pan-HDAC Inhibitor Givinostat in Improving Muscle Function and Correcting Drivers of</description>
</item>
<item>
<title>Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics</title>
<link>https://6ix.com/company/tenaya-therapeutics-inc/news/tenaya-therapeutics-enters-into-research-collaboration-with-alnylam-pharmaceuticals-to-identify-and-validate-novel-genetic-targets-for-cardiovascular-disease-therapeutics-33</link>
<guid isPermaLink="true">https://6ix.com/company/tenaya-therapeutics-inc/news/tenaya-therapeutics-enters-into-research-collaboration-with-alnylam-pharmaceuticals-to-identify-and-validate-novel-genetic-targets-for-cardiovascular-disease-therapeutics-33</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>Agreement Combines Tenaya’s Expertise in Identification and Validation ofGenetic Heart Disease Targets with Alnylam’s Ability to Deliver Transformational</description>
</item>
<item>
<title>Tenaya Therapeutics to Participate in the Leerink Partners Global Healthcare Conference 2026</title>
<link>https://6ix.com/company/tenaya-therapeutics-inc/news/tenaya-therapeutics-to-participate-in-the-leerink-partners-global-healthcare-conference-2026</link>
<guid isPermaLink="true">https://6ix.com/company/tenaya-therapeutics-inc/news/tenaya-therapeutics-to-participate-in-the-leerink-partners-global-healthcare-conference-2026</guid>
<pubDate>Mon, 02 Mar 2026 21:05:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Company management will be participating in the upcoming Leerink Partners Global Healthcare Conference taking place from March 9-11, 2026 in Miami, Florida. Faraz Ali, Tenaya’s Chief Executive Officer,</description>
</item>
<item>
<title>Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones</title>
<link>https://6ix.com/company/tenaya-therapeutics-inc/news/tenaya-therapeutics-announces-2026-strategic-133000521</link>
<guid isPermaLink="true">https://6ix.com/company/tenaya-therapeutics-inc/news/tenaya-therapeutics-announces-2026-strategic-133000521</guid>
<pubDate>Fri, 09 Jan 2026 13:30:00 GMT</pubDate>
<description>Aims to Build on Positive 2025 Interim TN-201 Results in First Half of 2026 with Longer-Term Follow-Up Data for Cohorts 1 and 2 from MyPEAK™-1 Trial of Adults with MYBPC3-Associated HCM Expects to Report One-Year Cohort 1 Data and Early Cohort 2 Data from RIDGE™-1 Study of TN-401 for PKP2-Associated ARVC in First Half of 2026 Plans to Pursue Alignment on Regulatory Pathways for Lead Gene Therapy Programs in 2026 Raised $60 Million in 4Q25 to Support Runway Through mid-2027 SOUTH SAN FRANCISCO, C</description>
</item>
<item>
<title>Tenaya Therapeutics Announces Pricing of Public Offering</title>
<link>https://6ix.com/company/tenaya-therapeutics-inc/news/tenaya-therapeutics-announces-pricing-public-051600342</link>
<guid isPermaLink="true">https://6ix.com/company/tenaya-therapeutics-inc/news/tenaya-therapeutics-announces-pricing-public-051600342</guid>
<pubDate>Fri, 12 Dec 2025 05:16:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the pricing of its underwritten public offering of 50,000,000 total units for gross proceeds of $60 million prior to deducting underwriting discounts and commissions and offering expenses. Tenaya intends to u</description>
</item>
<item>
<title>Tenaya Therapeutics Announces Proposed Public Offering</title>
<link>https://6ix.com/company/tenaya-therapeutics-inc/news/tenaya-therapeutics-announces-proposed-public-210200464</link>
<guid isPermaLink="true">https://6ix.com/company/tenaya-therapeutics-inc/news/tenaya-therapeutics-announces-proposed-public-210200464</guid>
<pubDate>Thu, 11 Dec 2025 21:02:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it intends to offer and sell units consisting of common stock and warrants to purchase shares of common stock. Tenaya may also sell to certain investors, in lieu of units, pre-funded units consisting of</description>
</item>
<item>
<title>Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1™ Phase 1b/2a Clinical Trial of TN-201 Gene Therapy</title>
<link>https://6ix.com/company/tenaya-therapeutics-inc/news/tenaya-therapeutics-announces-rapid-resolution-210100839</link>
<guid isPermaLink="true">https://6ix.com/company/tenaya-therapeutics-inc/news/tenaya-therapeutics-announces-rapid-resolution-210100839</guid>
<pubDate>Thu, 11 Dec 2025 21:01:00 GMT</pubDate>
<description>MyPEAK-1 Protocol Amendments Agreed Upon with FDA; Tenaya Implementing Changes with SitesSOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced it has received official notification from the U.S. Food and Drug Administration (FDA) that the clinical hold on the My</description>
</item>
<item>
<title>Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC</title>
<link>https://6ix.com/company/tenaya-therapeutics-inc/news/tenaya-therapeutics-reports-positive-interim-210100169</link>
<guid isPermaLink="true">https://6ix.com/company/tenaya-therapeutics-inc/news/tenaya-therapeutics-reports-positive-interim-210100169</guid>
<pubDate>Thu, 11 Dec 2025 21:01:00 GMT</pubDate>
<description>TN-401 was Well Tolerated at 3E13 vg/kg dose Robust Transduction and Demonstrated Increases in PKP2 Protein Levels in First Two Patients at Week 8Clinically Meaningful Reductions in Arrhythmia Burden Observed in First Two Patients with More Than Six Months of Follow-UpTenaya Management to Host a Webcast Conference Call Thursday, December 11 at 5:00 pm ET to Review Preliminary ResultsSOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinica</description>
</item>
<item>
<title>Tenaya Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/tenaya-therapeutics-inc/news/tenaya-therapeutics-reports-third-quarter-120000271</link>
<guid isPermaLink="true">https://6ix.com/company/tenaya-therapeutics-inc/news/tenaya-therapeutics-reports-third-quarter-120000271</guid>
<pubDate>Mon, 10 Nov 2025 12:00:00 GMT</pubDate>
<description>Presentation of MyPEAK-1 Data and the American Heart Association Scientific Sessions Showed Consistent, Deeper, and Durable Improvement in Measures of Hypertrophy for Cohort 1 Patients Initial TN-201 Cohort 2 Data Demonstrated Early Dose Responsive Increases in TN-201 Transduction and MyBP-C Protein Expression Completed Dosing in Cohort 2 of RIDGE™-1 Trial of TN-401 for PKP2-associated ARVC; Cohort 1 Data On Track for Fourth Quarter Company Presentation Tenaya Management to Review New MyPEAK-1 D</description>
</item>
<item>
<title>Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy</title>
<link>https://6ix.com/company/tenaya-therapeutics-inc/news/tenaya-therapeutics-presents-promising-interim-162500815</link>
<guid isPermaLink="true">https://6ix.com/company/tenaya-therapeutics-inc/news/tenaya-therapeutics-presents-promising-interim-162500815</guid>
<pubDate>Sat, 08 Nov 2025 16:25:00 GMT</pubDate>
<description>MyPEAK-1 Data Presented During Late-Breaking Session at AHA Scientific Sessions 2025 with Simultaneous Publication in Cardiovascular Research TN-201 Has Been Generally Well Tolerated at Both Doses Longer-term Follow Up of Cohort 1 Patients Showed Consistent, Deeper, and Durable Improvement in Measures of Hypertrophy Initial Cohort 2 Data Demonstrated Early Dose Responsive Increases in TN-201 Transduction and MyBP-C Protein Expression Tenaya Management to Host Webcast Call for Analysts and Invest</description>
</item>
<item>
<title>Tenaya Therapeutics Announces New Clinical Data for TN-201 Gene Therapy will be Featured in Late-Breaking Presentation at the American Heart Association Scientific Sessions 2025</title>
<link>https://6ix.com/company/tenaya-therapeutics-inc/news/tenaya-therapeutics-announces-clinical-data-223000961</link>
<guid isPermaLink="true">https://6ix.com/company/tenaya-therapeutics-inc/news/tenaya-therapeutics-announces-clinical-data-223000961</guid>
<pubDate>Tue, 04 Nov 2025 22:30:00 GMT</pubDate>
<description>Oral Presentation on Saturday to Highlight Interim Safety and Efficacy Results from the MyPEAK™-1 Phase 1b/2a Clinical Trial in Adults with MYBPC3-Associated Hypertrophic Cardiomyopathy Second Late-Breaking Presentation on Sunday to Showcase Results of Cellular Reprogramming Gene Therapy Treatment in Pig Model of Ischemic Heart Failure Tenaya Management to Host Webcast Conference Call on Monday, November 10, 2025, to Review MyPEAK-1 Data SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE</description>
</item>
<item>
<title>Tenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicines Virtual Conference</title>
<link>https://6ix.com/company/tenaya-therapeutics-inc/news/tenaya-therapeutics-participate-h-c-200500229</link>
<guid isPermaLink="true">https://6ix.com/company/tenaya-therapeutics-inc/news/tenaya-therapeutics-participate-h-c-200500229</guid>
<pubDate>Thu, 09 Oct 2025 20:05:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya’s Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Genetic Medicines Virtual Conference on Tuesday, October 14, 2025. Company management will host vir</description>
</item>
<item>
<title>Tenaya Therapeutics to Participate in Upcoming October Investor Conferences</title>
<link>https://6ix.com/company/tenaya-therapeutics-inc/news/tenaya-therapeutics-participate-upcoming-october-200500915</link>
<guid isPermaLink="true">https://6ix.com/company/tenaya-therapeutics-inc/news/tenaya-therapeutics-participate-upcoming-october-200500915</guid>
<pubDate>Thu, 02 Oct 2025 20:05:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya’s Chief Executive Officer, will participate in the following October investor and industry conferences. Details are below: Cell & Gene Meeting on the Mesa Date: Monday, October 6Time: 8</description>
</item>
<item>
<title>Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/tenaya-therapeutics-inc/news/tenaya-therapeutics-reports-inducement-grants-200500713</link>
<guid isPermaLink="true">https://6ix.com/company/tenaya-therapeutics-inc/news/tenaya-therapeutics-reports-inducement-grants-200500713</guid>
<pubDate>Thu, 18 Sep 2025 20:05:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it granted stock options to purchase an aggregate of 202,000 shares of Tenaya common stock to two new non-executive employees in connection with the commencement of their employment. The stock options ha</description>
</item>
<item>
<title>Tenaya Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference</title>
<link>https://6ix.com/company/tenaya-therapeutics-inc/news/tenaya-therapeutics-participate-morgan-stanley-200500342</link>
<guid isPermaLink="true">https://6ix.com/company/tenaya-therapeutics-inc/news/tenaya-therapeutics-participate-morgan-stanley-200500342</guid>
<pubDate>Tue, 02 Sep 2025 20:05:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya’s Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025, at 4:50 pm ET. The live web</description>
</item>
<item>
<title>Tenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025</title>
<link>https://6ix.com/company/tenaya-therapeutics-inc/news/tenaya-therapeutics-presents-interim-data-141500764</link>
<guid isPermaLink="true">https://6ix.com/company/tenaya-therapeutics-inc/news/tenaya-therapeutics-presents-interim-data-141500764</guid>
<pubDate>Sun, 31 Aug 2025 14:15:00 GMT</pubDate>
<description>Largest Noninterventional Natural History Study of People Under 18 with MYBPC3-associated HCM with More than 200 Participants 93% of MyClimb Participants had the Nonobstructive Form of HCM for Which There Are No Approved Therapeutics Genotypic Status Identified as a Significant Predictor of Risk and Left Ventricular Mass Index May Serve as a Surrogate Marker for Poor Long-Term Outcomes SOUTH SAN FRANCISCO, Calif., Aug. 31, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clin</description>
</item>
<item>
<title>Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference</title>
<link>https://6ix.com/company/tenaya-therapeutics-inc/news/tenaya-therapeutics-participate-canaccord-genuity-120000015</link>
<guid isPermaLink="true">https://6ix.com/company/tenaya-therapeutics-inc/news/tenaya-therapeutics-participate-canaccord-genuity-120000015</guid>
<pubDate>Fri, 08 Aug 2025 12:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya’s Chief Executive Officer, will participate in the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025 at 11:30 am ET. The live webcast of the fireside chat may</description>
</item>
<item>
<title>Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/tenaya-therapeutics-inc/news/tenaya-therapeutics-reports-second-quarter-203000598</link>
<guid isPermaLink="true">https://6ix.com/company/tenaya-therapeutics-inc/news/tenaya-therapeutics-reports-second-quarter-203000598</guid>
<pubDate>Wed, 06 Aug 2025 20:30:00 GMT</pubDate>
<description>Enrollment Complete in Cohorts 1 and 2 of MyPEAK™-1 Phase 1b/2 Trial of TN-201 for MYBPC3-associated HCM; Positive DSMB Safety Review Enables Enrollment of Expansion Cohorts Cohort 1 of RIDGE™-1 Phase 1b Trial of TN-401 Enrolled and First PKP2-associated ARVC Patient Dosed in Cohort 2 Following DSMB Recommendation to Dose Escalate and Expand Data Readouts from Both TN-201 and TN-401 Clinical Programs Planned for the Fourth Quarter of 2025 Cash Runway into Second Half of 2026 SOUTH SAN FRANCISCO,</description>
</item>
</channel>
</rss>